ALT-M5 / Alteogen - LARVOL DELTA

A Novel Once-Monthly Incretin Fusion Protein for Effective Suppression of Weight Regain (OBESITY WEEK 2026) - No abstract available

Alteogen touts monthly obesity drug matching retatrutide in preclinical tests (Chosun Biz) - "Alteogen said on the 9th that its once-monthly obesity drug candidate, which applies its in-house ultra–long-acting platform, showed not only weight-loss effects in preclinical testing but also a tendency for less so-called yo-yo weight regain after dosing stopped. Alteogen's ultra–long-acting platform extends the dosing interval of its existing long-acting NexP platform and is being developed to shift from a 'once-weekly' dosing formulation to 'once-monthly' dosing."

Preclinical • Obesity